03 October 2020: Clinical Research
Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension
Zirui Hao 1BCDE , Yue Sun 1BF , Yingzhen Wen 1BF , Lijuan Cui 1BF , Guiping Li 1DF , Yan Liu 2AG*DOI: 10.12659/MSM.925987
Med Sci Monit 2020; 26:e925987
Table 2 Uric acid and ambulatory blood pressure at baseline and 3-month follow-up.
| Variables | With dapagliflozin (n=182) | Without dapagliflozin (n=304) | P |
|---|---|---|---|
| Serum uric acid (umol/L) | 416±53 | 410±47 | 0.16 |
| 24-h urine volume (mL) | 1780±236 | 1733±209 | 0.33 |
| 24-h urinary uric acid (mmol/24 h/1.73 m) | 2.6±0.4 | 2.5±0.4 | 0.62 |
| UACR (mg/mmol) | 43.6 (18.9–238.3) | 45.2 (20.1–260.1) | 0.09 |
| 24-h SBP (mmHg) | 132±13 | 133±14 | 0.41 |
| 24-h DBP (mmHg) | 79±12 | 78±13 | 0.51 |
| Daytime SBP (mmHg) | 137±16 | 137±17 | 0.96 |
| Daytime DBP (mmHg) | 83±15 | 84±14 | 0.75 |
| Nighttime SBP (mmHg) | 123±12 | 122±13 | 0.66 |
| Nighttime DBP (mmHg) | 74±13 | 73±12 | 0.38 |
| Serum uric acid (umol/L) | 387±40 | 404±42 | 0.006 |
| 24-h urine volume (mL) | 1838±207 | 1669±194 | |
| 24-h urinary uric acid (mmol/24 h/1.73 m) | 2.9±0.7 | 2.4±0.3 | 0.01 |
| UACR (mg/mmol) | 40.8 (16.5–207.6) | 45.6 (20.7–262.5) | 0.009 |
| 24-h SBP (mmHg) | 129±11 | 133±15 | 0.03 |
| 24-h DBP (mmHg) | 78±10 | 79±11 | 0.24 |
| Daytime SBP (mmHg) | 132±13 | 137±16 | 0.02 |
| Daytime DBP (mmHg) | 81±12 | 83±13 | 0.35 |
| Nighttime SBP (mmHg) | 121±11 | 122±11 | 0.19 |
| Nighttime DBP (mmHg) | 72±10 | 73±11 | 0.38 |
| UACR – urine albumin-creatinine ratio; SBP – systolic blood pressure; DBP – diastolic blood pressure; * | |||